Dr. Lin Qing, Founder of Lingyi Bio, Joins IBI EXPO Suzhou 2025 as AAV Gene Therapy Nears Commercialization

A Warm Spring Day Opens a New Chapter, the Pharmaceutical Industry Invites All Talents to the Grand Event.March 1, 2025 to March 2, 2025，IBI EXPO 2025 (3rd) Biopharmaceutical Innovation Industry ConferenceWill be inSuzhou International Expo CenterGrandly held.

Conference FocusCell therapy, gene therapy, novel antibody drugs, stem cells and regenerative medicine, gene editing, nucleic acid drugs, exosomes, novel deliveryetc.In the frontier field of biopharmaceutical technology, fromNew Drug R&D, Non-clinical Evaluation, CMC Development, Drug Registration, Clinical Trials, Commercial Transformationetc.The entire lifecycle of biopharmaceuticals will be covered, and leading enterprises from various细分 fields in China, emerging companies, as well as representatives of leading companies that have made significant progress in the past year will be invited to present an unprecedented annual event in the field of biopharmaceutical innovation.

Since AAV vectors were first used in human patients, AAV gene therapy has evolved over nearly 30 years and has become one of the popular tracks in the innovative drug field. According to publicly available information,As of June 21, 2024, eight AAV gene therapies have been approved for marketing worldwide, with over 900 pipelines concurrently under research and development.These therapies inRare diseases, tumor-related diseases, hematological disorders, retinal diseases, hereditary deafness, etc.Significant breakthroughs have been made in the field, bringing new treatment hope to many patients.Global AAV Gene Therapy Sales Reached $1.5 Billion Last Year, Expected to Reach $22.3 Billion by 2029. It can be seen that the future of AAV gene therapy is promising.

China’s AAV gene therapy started later compared to foreign countries, but it is developing very rapidly. This year, China's AAV gene therapy has achieved many significant breakthroughs.

Moreover, the rapid development of China's AAV gene therapy field is not only reflected in clinical progress but also in technological innovation and international cooperation. Multiple companies are actively exploring new technical pathways, aiming toImprove gene delivery efficiency, enhance treatment safety, and broaden the range of indications. For example, by optimizing AAV capsid design, developing new gene editing tools, and utilizing artificial intelligence-assisted drug discovery, the advancement of AAV gene therapy is continuously propelled.More precise, more efficient, more secureThe direction of development.

In addition, with the development of AAV gene therapy, it can also be seenFrom raw material supply, vector production, plasmid preparation to clinical trial services, a series of professional service providers have emerged, offering strong support for the research, development, and commercialization of AAV gene therapies. This has not only reduced R&D costs but also improved overall R&D efficiency, accelerating the clinical translation of innovative achievements.